× Industry Reports Services Press Release Contact us About us

Asia Pacific Monoclonal Antibodies Market Forecast 2027 By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use (Hospitals, Clinics), Research Report, Country Outlook (Japan, China, India, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: July 2021 | Publisher: Graphical Research Report ID: GR1894 | Delivery : PDF  Request Free Sample

Asia Pacific Monoclonal Antibodies Market size crossed USD 30 billion in 2020 and is anticipated to observe around 15% growth between 2021 and 2027.

Monoclonal antibodies refer to proteins having ability to mimic immune system against life-threating pathogens including viruses. Monoclonal antibody (mAb) products are directed specifically against the disease-causing factor to block its pathway.

Asia Pacific Monoclonal Antibodies Market

Get more details on this report - Request Free Sample PDF

Focus on discovery and development of novel mAb therapeutics to offer highly specific treatment to complex and severe diseases will stimulate the Asia Pacific monoclonal antibodies market growth. Government support to expand local manufacturing sector will majorly benefit regional industry players. Recently, Garvan Institute of Medical Research received nearly USD 590,000 funding by the Australian government to develop potential treatment as well as preventive therapies for COVID-19. Researchers in institute are developing human monoclonal antibodies that will bypass the genetic variability of people's own immune responses and offer immediate immunity. It is indicated for both, the treatment of COVID-19 and prevention to at-risk individuals.

In April 2021, GlaxoSmithKline Australia Pty Ltd (GSK) received provisional determination by the Therapeutic Goods Administration (TGA) for its monoclonal antibody treatment, SOTROVIMAB. This will help the company to fasten clinical development for promising medicines with preliminary data. Later, in May 2021, Zydus Cadila revealed that it is seeking Drugs Controller General of India (DCGI) permission to initiate human clinical trials of monoclonal antibodies cocktail considered as potential treatment of COVID-19.

Asia Pacific Market, By Type

Fully human monoclonal antibodies segment dominated the market with nearly 51% revenue share in 2020, owing to advances in development technologies. Use of phage display technologies exhibits great potential for parallelization, scalability, and miniaturization. For instance, one of the highest selling mAb therapeutics, Humira, was developed through phage display of human antibody libraries. Since its approval, the number of fully human monoclonal antibodies in the market continued to rise over period.

Asia Pacific Market, By Application

Oncology segment accounted for around 40% Asia Pacific monoclonal antibodies market share in 2020. Continued R&D has resulted in availability of substantial mAb products indicated for therapeutic applications in cancer treatment. Further, there are number of products in pipeline leading to several product launches in future. Along with disease prevalence, product availability will also act as growth contributing factor. In addition to these factors, government funding for cancer research to develop and commercialize highly effective therapies catering to rising disease burden in the region will continue to influence the segment demand.

Asia Pacific Market, By End-use

Hospitals segment revenue is set to reach USD 34 billion by 2027. Patient preference for hospitals due to availability of newer therapeutics and skilled specialists will fuel the segment growth. Furthermore, hospitals have greater accessibility and distribution of novel and advanced treatment alternatives.

Asia Pacific Market, By Country

China monoclonal antibodies market held 63% revenue share in 2020, attributed to the expanding local manufacturing industry and developing biologic therapeutics sector. Adoption of mAb technologies from international leading players in the country has resulted in high specificity and expression. For instance, TNFα based monoclonal antibodies were developed to treat rheumatoid arthritis. Such developments allowed firms to cater to increasing patient population associated with several conditions in the country.

Competitive Industry Landscape

Few of the major Asia Pacific monoclonal antibodies market players include Takeda Pharmaceuticals, F. Hoffmann-La Roche, AbbVie Inc., Amgen, Bristol Myers Squibb, and Novartis AG.

These companies are continuously innovating their product and are involved in collaborations to cater growing patient pool. For instance, in May 2021, Cipla announced the launch of Roche's COVID antibody cocktail in India. This will help Roche to distribute its product across India in partnership with Cipla to leading hospitals and COVID-19 treatment centres.
 

Frequently Asked Question(FAQ) :

The market for monoclonal antibodies in Asia Pacific generated USD 30 billion in 2020 and should grow at a 15% CAGR up to 2027.
The industry for monoclonal antibodies in Asia Pacific captured over 51% revenue share in 2020 led by continuous advances in development technologies.
Oncology segment held more than 40% share of Asia Pacific industry in terms of revenue during 2020.
The market size for monoclonal antibodies in Asia Pacific from hospitals could surpass USD 34 billion in terms of annual revenue by the end of 2027.
China captured over 63% revenue share of Asia Pacific industry in 2020 and will expand with maturing biologic therapeutic sector.

Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]